Michael A. Yassa, Ph.D.
Dr. Yassa is recognized for his highly cited work on memory alterations in aging and Alzheimer’s disease and as a leader in the neuroscience of learning and memory. His laboratory develops innovative high-resolution human imaging techniques and digital cognitive tests to probe brain circuits at fine levels of detail. Over the last 15 years, his work has focused on digital and neural biomarker development for age-related cognitive decline and dementia. Yassa’s work has led to over 120 peer-reviewed publications and over $50M in federal grant funding. He began his academic career at the Johns Hopkins University, then moved to the University of California Irvine, where he is now professor and James L. McGaugh Endowed Chair with appointments in Neurobiology, Neurology, and Psychiatry. He is also director of the world-renowned Center for the Neurobiology of Learning and Memory, founded in 1983. Yassa earned his BA in Neuroscience and MA in Cognitive Neuroscience and Psychology from the Johns Hopkins University and his PhD in Neurobiology from the University of California, Irvine.
Adele Gilpin, Ph.D., J.D.
Dr. Gilpin works at the interface of clinical trials design and conduct, and FDA regulatory requirements. As a clinical trials methodologist and a Food and Drug Regulatory attorney, she primarily works on bringing new neurological medical devices to market, with particular attention to the FDA hurdles in investigational products, and complying with FDA requirements. Her work has included designing and conducting multicenter drug and device clinical trials, and chairing or participating in multiple Institutional Review Boards and Data and Safety Monitoring Boards. Gilpin brings decades of experience both in academic medical research – at the Johns Hopkins School of Public Health and the University of Maryland School of Medicine – and in FDA legal/regulatory practice – at AMLAW 100 law firm bioscience practices. Gilpin is an adjunct visiting professor at the Center for the Neurobiology of Learning and Memory at the University of California Irvine. She has a BA in Psychology, an MA and PhD in Quantitative Psychology from Temple University, and a JD from Georgetown University Law Center.
Michael Yassa, Ph.D.
Co-Founder and Chief Scientific Advisor
Dr. Yassa is recognized as a leader in the neuroscience of memory and memory loss in Alzheimer’s disease and chief developer of the Augnition Labs technology.
Adele Gilpin, Ph.D., J.D.
Co-Founder and Chief Regulatory Officer
Dr. Gilpin serves as head of regulatory affairs for Augnition and is highly experienced in clinical trials methodology and FDA regulatory requirements.
Marco Peters, Ph.D.
Co-Founder and Scientific Advisor
Dr. Peters is a leader in translational research, target discovery, and small molecule discovery for CNS indications, with emphasis on memory loss and plasticity.
Andrew Anderson, B.Sc., M.B.A.
Principal Technical Advisor
Mr. Anderson serves as Principal Technical Advisor for Augnition, managing an ecosystem of technology partners to develop and commercialize platform applications.
Ali Kennedy Scott, B.Com., M.F.A.
Head of Corporate Development and Strategy
Ms. Kennedy Scott is a management consultant with extensive experience working with private equity firms and early-stage ventures in the health and technology space.
Laurence Unger, M.B.A.
Head of Finance
Ms. Unger is an experienced executive and investment professional with a diverse background in hedge fund management, start-up and business development.